Exosomes Pipeline Shows Strong Momentum as 100+ Pharma Companies in the Race | DelveInsight

DelveInsight's "Exosomes Pipeline Insight 2026" report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Exosomes Pipeline? @ https://www.delveinsight.com/sample-request/exosomes-pipeline-insight [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Exosomes Pipeline Report

* On March 23, 2026- Direct Biologics LLC initiated a Phase III, multicenter, randomized, double-blinded, placebo-controlled trial for the treatment of moderate-to-severe Acute Respiratory Distress Syndrome (ARDS). To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
* DelveInsight's Exosomes Pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Exosomes treatment.
* The leading Exosomes Companies such as Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, EXO Biologics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd. and others.
* Promising Exosomes Therapies such as Olmutinib, Zofin, AGLE-102 , and others.

Want to know which companies are leading innovation in Exosomes? @ Exosomes Clinical Trials Assessment [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Exosomes Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Exosomes Pipeline Report also highlights the unmet needs with respect to the Exosomes.

Exosomes Overview

Exosomes are small extracellular vesicles ( almost equal to 40-160 nm) released by most cell types through the fusion of multivesicular bodies with the plasma membrane, which liberates intraluminal vesicles into the extracellular space. They are widely present in biological fluids such as blood, urine, breast milk, and semen, and can be taken up by distant cells. Through the transfer of bioactive cargo, exosomes play a crucial role in cell-cell communication and can influence disease progression. Their contents including proteins, lipids, nucleic acids, amino acids, and metabolites reflect their cell of origin and are shaped during their biogenesis in the endosomal pathway. Owing to these properties, exosomes are being actively explored for diagnostic and therapeutic applications, particularly in drug discovery. They are commonly isolated using techniques such as differential centrifugation and polymer-based precipitation.

Exosomes Emerging Drugs Profile

* CAP-1002: Capricor Therapeutics

Capricor's CAP-1002 consists of cardiosphere-derived cells (CDCs), a type of cardiac progenitor cell originally discovered in the laboratory of its scientific founder, Eduardo Marban. These CDCs have been extensively studied, with over 100 peer-reviewed publications and clinical administration in more than 200 patients across multiple trials. CAP-1002 works by releasing exosomes, small vesicles that influence immune responses and promote tissue repair. These exosomes are primarily taken up by macrophages and T cells, triggering regenerative processes and modulating immune activity. The therapy is currently in the registration stage for the treatment of Duchenne Muscular Dystrophy.

* Debamestrocel: BrainStorm Cell Therapeutics

Debamestrocel (NurOwn) consists of autologous bone marrow-derived mesenchymal stem cells (MSCs) that are cultured to secrete elevated levels of neurotrophic factors, supporting neuronal survival and repair. These MSC-NTF cells combine the immunomodulatory effects of MSCs with enhanced neurotrophic activity, partly mediated through exosome-based delivery of factors such as GDNF. The therapy is manufactured from a patient's own MSCs, expanded and differentiated ex vivo without genetic modification, and then re-administered. It is currently in Phase III development for the treatment of Amyotrophic Lateral Sclerosis, with additional programs in multiple neurological disorders at earlier stages.

* AGLE-102: Aegle Therapeutics

AGLE-102 is an allogeneic extracellular vesicle (EV) therapy derived from mesenchymal stem cells obtained from healthy donors. It consists of MSC-derived vesicles that deliver proteins, genetic material, and regenerative factors to support repair in damaged tissues. The therapy is currently in Phase I/II development for the treatment of burns and Epidermolysis Bullosa Dystrophica, and is also being explored at the preclinical stage for Graft-versus-Host Disease.

* RioMSK001: RION

RioMSK001 is an innovative therapeutic candidate developed by Rion for musculoskeletal disorders. It is designed to address degenerative joint conditions with a focus on improving function and reducing disease burden. According to the company's pipeline, the therapy is currently in early clinical evaluation. It is in Phase I development for the treatment of Knee Osteoarthritis.

* HEPATOSOME: ExoStemTech

HEPATOSOME is an investigational therapy being developed by ExoStemTech. It is designed as a novel approach targeting liver-related disorders through advanced therapeutic mechanisms. The candidate is currently undergoing early-stage research and evaluation. At present, it is in preclinical development for the treatment of Liver Fibrosis.

If you're tracking ongoing Exosomes Clinical trials, this press release is a must-read @ Exosomes Treatment Drugs [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Exosomes Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment.
* Exosomes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market.

Exosomes Companies

Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, EXO Biologics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd. and others.

Exosomes Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Exosomes Products have been categorized under various Molecule types such as,

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

From emerging drug candidates to competitive intelligence, the Exosomes Pipeline Report @ Exosomes Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Exosomes Pipeline Report

* Coverage- Global
* Exosomes Companies- Capricor Therapeutics, BrainStorm Cell Therapeutics, Aegle Therapeutics, EXO Biologics, RION, S&E bio, Shine-On Biomedical Co., Ltd., ImmVira, ILIAS Biologics, Secretome Therapeutics, VesiCURE Therapeutics, Everzom, Brexogen, ShiftBio, Conveyxo, Exogenus Therapeutics, Coya Therapeutics, VivaZome Therapeutics, NurExone, Ji Yan Biomedical Co., Ltd. and others.
* Exosomes Therapies- Olmutinib, Zofin, AGLE-102 , and others.
* Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Exosomes Treatment landscape in this detailed analysis @ Exosomes Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/exosomes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Exosomes: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Exosomes - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* RioMSK001: RION
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HEPATOSOME: ExoStemTech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug profiles in the detailed report.....
* Inactive Products
* Exosomes Key Companies
* Exosomes Key Products
* Exosomes - Unmet Needs
* Exosomes - Market Drivers and Barriers
* Exosomes - Future Perspectives and Conclusion
* Exosomes Analyst Views
* Exosomes Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=exosomes-pipeline-shows-strong-momentum-as-100-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/report-store/exosomes-pipeline-insight
Country: United States
Website: https://www.delveinsight.com/report-store/exosomes-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.